Status: Recruiting
Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
The main purpose of this study is to determine the effectiveness of the study drug pacritinib in people with relapsed or refractory lymphoproliferative disorders.
Participants needed: 100
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: University of Michigan Rogel Cancer CenterUpdated: Jan 29, 2026Locations: 6
Eligibility criteria
Written informed consent and HIPAA authorization for release of personal health... [+9]
History of, or a concurrent, clinically significant illness, medical condition o... [+20]